The Biotech Lottery Ticket
Perhaps the purest gamble of all lies in biotechnology. A company like Rocket Pharmaceuticals isn’t just selling a product, it’s betting on a scientific hypothesis. They are developing gene therapies for rare diseases, which is incredibly noble and, if successful, could be monumentally profitable.
The key word there is ‘if’. The path for any new drug is a minefield of clinical trials, regulatory approvals, and unforeseen complications. For every one that succeeds, countless others fail, taking billions in investor capital with them. Investing here is not for the faint of heart. It is, in essence, buying a very expensive, very complicated lottery ticket. The odds are long, but the potential jackpot is transformative.
What I find interesting is the idea of bundling these disparate gambles. Grouping these high-stakes ventures into a single theme, like the one found in the Thrill & Excitement, is a fascinating approach. It doesn’t remove the risk, of course, but it does spread the hope around. Instead of betting on one moonshot, you’re taking a small piece of several. It’s a strategy that acknowledges the high chance of failure for any single company but hopes that just one of them might strike gold. This isn't for your pension pot, mind you. It's for the small slice of your portfolio that you can afford to lose, but hope you won't.
